Clinical Trials Logo

Clinical Trial Summary

Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.


Clinical Trial Description

Phase III Study in Patients with Relapsed/Refractory Multiple Myeloma to compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone measured by progression-free survival (PFS) and to evaluate tumor response, duration of response (DR), overall survival (OS) and to rule out any effect of plitidepsin on the duration of the QT/QTc interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01102426
Study type Interventional
Source PharmaMar
Contact
Status Completed
Phase Phase 3
Start date June 2010
Completion date November 2017

See also
  Status Clinical Trial Phase
Recruiting NCT05427812 - Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2
Active, not recruiting NCT04093596 - Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Phase 1
Not yet recruiting NCT05498545 - Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Recruiting NCT04973605 - A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05376345 - BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Withdrawn NCT05980507 - An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma Phase 1
Active, not recruiting NCT04601935 - A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Terminated NCT06160609 - Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM Phase 1/Phase 2
Recruiting NCT03309111 - Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Phase 1
Recruiting NCT06049290 - A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05259839 - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma Phase 1
Terminated NCT03318861 - Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma Phase 1
Active, not recruiting NCT03590652 - Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma Phase 2
Completed NCT01794520 - Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04142619 - Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) Phase 1
Completed NCT01849848 - Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma Phase 2
Completed NCT01794507 - A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Phase 1
Active, not recruiting NCT05160584 - A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Terminated NCT03287908 - A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT03489525 - MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma Phase 1